Activated melanoma vessels: A sticky point for successful immunotherapy. Issue 11 (19th October 2020)

• Record Type: Journal Article
• Authors: Weishaupt, Carsten; Goerge, Tobias; Loser, Karin
• Other Names: Gaffal Evelyn guestEditor.
• Is Part Of: Experimental dermatology. Volume 29:Issue 11(2020)
• Page Start: 1046
• Page End: 1054
• Publication Date: 2020-10-19
• Subjects: adhesion molecules -- animal model -- drug carriers -- lymphocyte homing receptors -- xenografts; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.14203
• Languages: English
• ISSNs: 0906-6705

Abstract

Abstract: Metastatic melanoma is a devastating disease with a marginal—albeit increasing—hope for cure. Melanoma has a high mutation rate which correlates to the expression of numerous neo‐antigens and thus is associated with the potential to induce and strengthen effective antitumoral immunity. However, the incomplete and potentially insufficient response to established immunotherapies (response rates usually do not markedly exceed 60%) already points to the need of further studies to improve treatment strategies. Multiple tumor escape mechanisms that allow melanoma to evade from antitumoral immune responses have been characterized and must be overcome to achieve a better clinical efficacy of immunotherapies. Recently, promising progress has been made in targeting tumor vasculature to control and increase the infiltration of tumors with effector lymphocytes. It has been hypothesized that amplified lymphocytic infiltrates in melanoma metastases result in a switch of the tumor microenvironment from a non‐inflammatory to an inflammatory state. In this view point essay, we discuss the requirements for successful homing of lymphocytes to melanoma tissue and we present a mouse melanoma xenograft model that allows the investigation of human tumor vessels in vivo. Furthermore, current clinical studies dealing with the activation of melanoma vasculature for enhanced effectiveness of immunotherapy protocols are presented and open questions for routine clinical application are addressed.